{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    13,
    14,
    15,
    17,
    18,
    19,
    20,
    21,
    22,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective (Part A)",
        "text": "To determine whether BIVV009 administration results in a ≥2 g/dL increase in hemoglobin (Hgb) levels or increases Hgb to ≥12 g/dL and obviates the need for blood transfusion during treatment in patients with primary CAgD who have a recent history of blood transfusion.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective (Part A)",
        "text": "To assess the effect of BIVV009 on clinical events and laboratory parameters related to hemolysis and anemia in patients with primary CAgD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_4",
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Quality of Life Objective (Part A)",
        "text": "To assess the effect of BIVV009 on quality of life (QOL) in patients with primary CAgD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Safety Objective (Part A)",
        "text": "To evaluate the overall safety and tolerability of BIVV009 in patients with primary CAgD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_21",
          "ep_22",
          "ep_23",
          "ep_24"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Exploratory Objective (Part A) - Complications",
        "text": "To assess the effect of BIVV009 on specific complications of CAgD (acrocyanosis, Raynaud’s syndrome, hemoglobinuria, and thromboembolism)",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12",
          "ep_19"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Exploratory Objective (Part A) - Biomarkers",
        "text": "To evaluate the effect of BIVV009 on certain disease-related biomarkers in patients with primary CAgD",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_14",
          "ep_15",
          "ep_16",
          "ep_17",
          "ep_18"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Exploratory Objective (Part A) - Pharmacokinetics",
        "text": "To evaluate the pharmacokinetics of BIVV009",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_25",
          "ep_26"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Exploratory Objective (Part A) - Immunogenicity",
        "text": "To evaluate the immunogenicity of BIVV009",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_29"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Primary Objective (Part B)",
        "text": "The primary objective of Part B is to evaluate the long-term safety and tolerability of BIVV009 in patients with primary CAgD.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_21",
          "ep_22",
          "ep_23",
          "ep_24"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Secondary Objective (Part B)",
        "text": "The secondary objective of Part B is to investigate the durability of response during long-term treatment with BIVV009 in patients with primary CAgD.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6",
          "ep_2",
          "ep_4",
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective (Part B) - Home Infusion",
        "text": "To describe the safety and patient satisfaction with the convenience of home infusions with BIVV009 in a subset of patients",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_24",
          "ep_30"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint (Part A)",
        "text": "The primary efficacy endpoint is the responder rate as defined in Table 2 (≥2 g/dL increase in Hgb or Hgb ≥12 g/dL and no transfusion from Week 5 to 26).",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint - Bilirubin",
        "text": "Mean change from baseline in bilirubin (excluding patients with Gilbert’s Syndrome) at the treatment assessment endpoint",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint - FACIT-Fatigue",
        "text": "Mean change from baseline in QOL, as assessed by the change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale scores at the treatment assessment endpoint",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Endpoint - LDH",
        "text": "Mean change from baseline in lactate dehydrogenase (LDH) at the treatment assessment endpoint",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Endpoint - Transfusions",
        "text": "Number of transfusions and number of units after the first 5 weeks of study drug administration",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Endpoint - Hgb",
        "text": "Mean change from baseline in Hgb at the treatment assessment endpoint",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Exploratory Efficacy Endpoint - Time to Transfusion",
        "text": "Time to first transfusion after the first 5 weeks of study drug administration",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Exploratory Efficacy Endpoint - EQ-5D-5L",
        "text": "Mean change from baseline in QOL, as assessed by the change in the five level EuroQol - five dimensions questionnaire (EQ-5D-5L) scores at the treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_9",
        "name": "Exploratory Efficacy Endpoint - SF-12",
        "text": "Mean change from baseline in QOL, as assessed by the change in the 12-Item Short Form Survey (SF-12®) at the end of treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_10",
        "name": "Exploratory Efficacy Endpoint - Symptomatic Anemia",
        "text": "Incidence of solicited symptomatic anemia at EOT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Efficacy Endpoint - Hgb Threshold",
        "text": "Proportion of patients with Hgb level of ≥12 g/dL at the treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Exploratory Efficacy Endpoint - Thromboembolism",
        "text": "Incidence of thromboembolic events after the first 5 weeks of study drug administration",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_13",
        "name": "Exploratory Efficacy Endpoint - Normalization Time",
        "text": "Median time to normalization of bilirubin, LDH, and haptoglobin",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_14",
        "name": "Exploratory Efficacy Endpoint - Haptoglobin Normalization",
        "text": "Proportion of patients normalizing haptoglobin at the treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_15",
        "name": "Exploratory Efficacy Endpoint - Bilirubin Normalization",
        "text": "Proportion of patients normalizing bilirubin at the treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_16",
        "name": "Exploratory Efficacy Endpoint - LDH Normalization",
        "text": "Proportion of patients normalizing LDH at the treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_17",
        "name": "Exploratory Efficacy Endpoint - PGIC",
        "text": "Patient’s Global Impression of Change (PGIC) to assess patient’s perception of changes in CAgD disease burden at EOT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_18",
        "name": "Exploratory Efficacy Endpoint - PGIS",
        "text": "Patient’s Global Impression of [Fatigue] Severity (PGIS) to assess patient’s perception of changes in fatigue at EOT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_19",
        "name": "Exploratory Efficacy Endpoint - Circulatory Symptoms",
        "text": "Incidence of disabling circulatory symptoms at EOT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_20",
        "name": "Exploratory Efficacy Endpoint - Resource Utilization",
        "text": "Total healthcare resource utilization at EOT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_21",
        "name": "Safety Outcome Measures - General",
        "text": "Adverse events (AEs), serious AEs, clinical laboratory evaluations, SLE panel, vital sign measurements, electrocardiograms (ECGs), physical examination findings, and serum disease-related biomarkers.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_22",
        "name": "Safety Outcome Measures - Hemolytic Breakthrough",
        "text": "Hemolytic breakthrough (rapid fall in Hgb ≥2 g/dL associated with an increase in LDH/bilirubin and/or decrease in haptoglobin since the last scheduled visit) through the EOT at Week 26",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_23",
        "name": "Safety Outcome Measures - Infections",
        "text": "Infections of ≥ Grade 3 severity (ie, requiring IV antibiotics)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_24",
        "name": "Safety Outcome Measures - Home Infusion",
        "text": "For patients with home infusions, safety assessments will additionally include AEs with onset within 24 hours of the infusion",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_25",
        "name": "Pharmacokinetic Endpoint - Concentration",
        "text": "Plasma concentrations of BIVV009",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_26",
        "name": "Pharmacokinetic Endpoint - Parameters",
        "text": "PK parameters. Appropriate exposure parameters (Cmax, AUC) will be derived using a population approach.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_27",
        "name": "Pharmacodynamic Primary Outcome Measure",
        "text": "Wieslab-CP",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_28",
        "name": "Exploratory Complement System Measures",
        "text": "CH50, Total C4, C1q, C1s",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_29",
        "name": "Immunogenicity Outcome Measures",
        "text": "Pre-existing ADA and treatment-emergent ADA",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_30",
        "name": "Home Infusion Satisfaction",
        "text": "Satisfaction with home infusion after first home infusion and after four home infusion will be assessed in patients with home infusion",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand (Part A)",
        "populationSummary": "Adult patients with primary cold agglutinin disease (CAgD) who have a recent history of blood transfusion (Full Analysis Set) Summary measure: Proportion of responders with 95% exact Clopper-Pearson confidence interval.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Withdrawal from study",
            "text": "Any patient withdrawing from the study after Week 5 and prior to the Week 23 visit",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Use of prohibited CAgD therapies",
            "text": "Patients requiring other treatment for their CAgD in Part A",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Blood transfusion",
            "text": "Receipt of blood transfusion from Week 5 through Week 26",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV009 (6.5 g or 7.5 g based on weight) IV infusion on Day 0, Day 7, and every 14 days thereafter",
        "analysisPopulation": "Adult patients with primary cold agglutinin disease (CAgD) who have a recent history of blood transfusion (Full Analysis Set)",
        "variableOfInterest": "Responder rate (≥2 g/dL increase in Hgb or Hgb ≥12 g/dL and no blood transfusion from Week 5 through Week 26)",
        "summaryMeasure": "Proportion of responders with 95% exact Clopper-Pearson confidence interval"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand - Hemoglobin Change",
        "populationSummary": "Adult patients with primary cold agglutinin disease (CAgD) who have a recent history of blood transfusion (Full Analysis Set) Summary measure: Mean change from baseline analyzed using a one-sample t-test.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_6",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug prior to Week 26",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV009 (6.5 g or 7.5 g based on weight) IV infusion",
        "analysisPopulation": "Adult patients with primary cold agglutinin disease (CAgD) who have a recent history of blood transfusion (Full Analysis Set)",
        "variableOfInterest": "Mean change from baseline in Hgb at the treatment assessment endpoint (Weeks 23, 25, and 26)",
        "summaryMeasure": "Mean change from baseline analyzed using a one-sample t-test"
      }
    ],
    "summary": {
      "primaryObjectives": 2,
      "secondaryObjectives": 4,
      "exploratoryObjectives": 5,
      "totalEndpoints": 30,
      "totalEstimands": 2
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective (Part A)",
        "text": "To determine whether BIVV009 administration results in a ≥2 g/dL increase in hemoglobin (Hgb) levels or increases Hgb to ≥12 g/dL and obviates the need for blood transfusion during treatment in patients with primary CAgD who have a recent history of blood transfusion.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective (Part A)",
        "text": "To assess the effect of BIVV009 on clinical events and laboratory parameters related to hemolysis and anemia in patients with primary CAgD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_4",
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Quality of Life Objective (Part A)",
        "text": "To assess the effect of BIVV009 on quality of life (QOL) in patients with primary CAgD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Safety Objective (Part A)",
        "text": "To evaluate the overall safety and tolerability of BIVV009 in patients with primary CAgD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_21",
          "ep_22",
          "ep_23",
          "ep_24"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Exploratory Objective (Part A) - Complications",
        "text": "To assess the effect of BIVV009 on specific complications of CAgD (acrocyanosis, Raynaud’s syndrome, hemoglobinuria, and thromboembolism)",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12",
          "ep_19"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Exploratory Objective (Part A) - Biomarkers",
        "text": "To evaluate the effect of BIVV009 on certain disease-related biomarkers in patients with primary CAgD",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_14",
          "ep_15",
          "ep_16",
          "ep_17",
          "ep_18"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Exploratory Objective (Part A) - Pharmacokinetics",
        "text": "To evaluate the pharmacokinetics of BIVV009",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_25",
          "ep_26"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Exploratory Objective (Part A) - Immunogenicity",
        "text": "To evaluate the immunogenicity of BIVV009",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_29"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Primary Objective (Part B)",
        "text": "The primary objective of Part B is to evaluate the long-term safety and tolerability of BIVV009 in patients with primary CAgD.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_21",
          "ep_22",
          "ep_23",
          "ep_24"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Secondary Objective (Part B)",
        "text": "The secondary objective of Part B is to investigate the durability of response during long-term treatment with BIVV009 in patients with primary CAgD.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6",
          "ep_2",
          "ep_4",
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective (Part B) - Home Infusion",
        "text": "To describe the safety and patient satisfaction with the convenience of home infusions with BIVV009 in a subset of patients",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_24",
          "ep_30"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint (Part A)",
        "text": "The primary efficacy endpoint is the responder rate as defined in Table 2 (≥2 g/dL increase in Hgb or Hgb ≥12 g/dL and no transfusion from Week 5 to 26).",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint - Bilirubin",
        "text": "Mean change from baseline in bilirubin (excluding patients with Gilbert’s Syndrome) at the treatment assessment endpoint",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint - FACIT-Fatigue",
        "text": "Mean change from baseline in QOL, as assessed by the change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale scores at the treatment assessment endpoint",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Endpoint - LDH",
        "text": "Mean change from baseline in lactate dehydrogenase (LDH) at the treatment assessment endpoint",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Endpoint - Transfusions",
        "text": "Number of transfusions and number of units after the first 5 weeks of study drug administration",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Endpoint - Hgb",
        "text": "Mean change from baseline in Hgb at the treatment assessment endpoint",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Exploratory Efficacy Endpoint - Time to Transfusion",
        "text": "Time to first transfusion after the first 5 weeks of study drug administration",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Exploratory Efficacy Endpoint - EQ-5D-5L",
        "text": "Mean change from baseline in QOL, as assessed by the change in the five level EuroQol - five dimensions questionnaire (EQ-5D-5L) scores at the treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_9",
        "name": "Exploratory Efficacy Endpoint - SF-12",
        "text": "Mean change from baseline in QOL, as assessed by the change in the 12-Item Short Form Survey (SF-12®) at the end of treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_10",
        "name": "Exploratory Efficacy Endpoint - Symptomatic Anemia",
        "text": "Incidence of solicited symptomatic anemia at EOT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Efficacy Endpoint - Hgb Threshold",
        "text": "Proportion of patients with Hgb level of ≥12 g/dL at the treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Exploratory Efficacy Endpoint - Thromboembolism",
        "text": "Incidence of thromboembolic events after the first 5 weeks of study drug administration",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_13",
        "name": "Exploratory Efficacy Endpoint - Normalization Time",
        "text": "Median time to normalization of bilirubin, LDH, and haptoglobin",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_14",
        "name": "Exploratory Efficacy Endpoint - Haptoglobin Normalization",
        "text": "Proportion of patients normalizing haptoglobin at the treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_15",
        "name": "Exploratory Efficacy Endpoint - Bilirubin Normalization",
        "text": "Proportion of patients normalizing bilirubin at the treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_16",
        "name": "Exploratory Efficacy Endpoint - LDH Normalization",
        "text": "Proportion of patients normalizing LDH at the treatment assessment endpoint",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_17",
        "name": "Exploratory Efficacy Endpoint - PGIC",
        "text": "Patient’s Global Impression of Change (PGIC) to assess patient’s perception of changes in CAgD disease burden at EOT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_18",
        "name": "Exploratory Efficacy Endpoint - PGIS",
        "text": "Patient’s Global Impression of [Fatigue] Severity (PGIS) to assess patient’s perception of changes in fatigue at EOT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_19",
        "name": "Exploratory Efficacy Endpoint - Circulatory Symptoms",
        "text": "Incidence of disabling circulatory symptoms at EOT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_20",
        "name": "Exploratory Efficacy Endpoint - Resource Utilization",
        "text": "Total healthcare resource utilization at EOT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_21",
        "name": "Safety Outcome Measures - General",
        "text": "Adverse events (AEs), serious AEs, clinical laboratory evaluations, SLE panel, vital sign measurements, electrocardiograms (ECGs), physical examination findings, and serum disease-related biomarkers.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_22",
        "name": "Safety Outcome Measures - Hemolytic Breakthrough",
        "text": "Hemolytic breakthrough (rapid fall in Hgb ≥2 g/dL associated with an increase in LDH/bilirubin and/or decrease in haptoglobin since the last scheduled visit) through the EOT at Week 26",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_23",
        "name": "Safety Outcome Measures - Infections",
        "text": "Infections of ≥ Grade 3 severity (ie, requiring IV antibiotics)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_24",
        "name": "Safety Outcome Measures - Home Infusion",
        "text": "For patients with home infusions, safety assessments will additionally include AEs with onset within 24 hours of the infusion",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_25",
        "name": "Pharmacokinetic Endpoint - Concentration",
        "text": "Plasma concentrations of BIVV009",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_26",
        "name": "Pharmacokinetic Endpoint - Parameters",
        "text": "PK parameters. Appropriate exposure parameters (Cmax, AUC) will be derived using a population approach.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_27",
        "name": "Pharmacodynamic Primary Outcome Measure",
        "text": "Wieslab-CP",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_28",
        "name": "Exploratory Complement System Measures",
        "text": "CH50, Total C4, C1q, C1s",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_29",
        "name": "Immunogenicity Outcome Measures",
        "text": "Pre-existing ADA and treatment-emergent ADA",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_30",
        "name": "Home Infusion Satisfaction",
        "text": "Satisfaction with home infusion after first home infusion and after four home infusion will be assessed in patients with home infusion",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand (Part A)",
        "populationSummary": "Adult patients with primary cold agglutinin disease (CAgD) who have a recent history of blood transfusion (Full Analysis Set) Summary measure: Proportion of responders with 95% exact Clopper-Pearson confidence interval.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Withdrawal from study",
            "text": "Any patient withdrawing from the study after Week 5 and prior to the Week 23 visit",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Use of prohibited CAgD therapies",
            "text": "Patients requiring other treatment for their CAgD in Part A",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Blood transfusion",
            "text": "Receipt of blood transfusion from Week 5 through Week 26",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV009 (6.5 g or 7.5 g based on weight) IV infusion on Day 0, Day 7, and every 14 days thereafter",
        "analysisPopulation": "Adult patients with primary cold agglutinin disease (CAgD) who have a recent history of blood transfusion (Full Analysis Set)",
        "variableOfInterest": "Responder rate (≥2 g/dL increase in Hgb or Hgb ≥12 g/dL and no blood transfusion from Week 5 through Week 26)",
        "summaryMeasure": "Proportion of responders with 95% exact Clopper-Pearson confidence interval"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand - Hemoglobin Change",
        "populationSummary": "Adult patients with primary cold agglutinin disease (CAgD) who have a recent history of blood transfusion (Full Analysis Set) Summary measure: Mean change from baseline analyzed using a one-sample t-test.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_6",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug prior to Week 26",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "BIVV009 (6.5 g or 7.5 g based on weight) IV infusion",
        "analysisPopulation": "Adult patients with primary cold agglutinin disease (CAgD) who have a recent history of blood transfusion (Full Analysis Set)",
        "variableOfInterest": "Mean change from baseline in Hgb at the treatment assessment endpoint (Weeks 23, 25, and 26)",
        "summaryMeasure": "Mean change from baseline analyzed using a one-sample t-test"
      }
    ]
  }
}